Compounding is where the GLP-1 supply economy actually lives. The FDA's 2022–2024 shortage designations created a window for 503A patient-specific compounders and 503B outsourcing facilities to produce semaglutide and tirzepatide at a fraction of branded prices. Telehealth platforms — Hims & Hers, Ro, LifeMD, Eucalyptus — built distribution on top of that channel.
The window closed once the agency declared the shortages resolved. Since then, the rules have been rewritten in pieces: Category 2 placement for BPC-157 and other research peptides; the April 30, 2026 FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the Outsourcing Facilities Association lawsuit; and a University of Colorado secret-shopper study finding 65–69 of 74 medspas still sold compounded GLP-1s in April 2026. The Partnership for Safe Medicines applauded the 503B proposal and plans to file a Federal Register comment ahead of the June 29 deadline; Orrick's May client memo told outsourcing facilities, weight-loss clinics, and telehealth platforms still leaning on compounded supply to consult counsel.
Stories here cover both the legal and economic dimensions. See #503a, #503b, #category-2, and #fda for adjacent threads.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
The Washington Post Health Brief published Thursday July 9, 2026 a column by reporter Megan R. Wilson titled 'The peptide showdown,' sustaining WaPo's coverage of the FDA compounding-peptide review through a second full policy-newsletter beat in 10 days. The column extends the framework established in WaPo's June 30 general-audience explainer 'Peptides Are Popular and Controversial. Why?' The July 9 piece keeps the newspaper's mainstream-media pressure focused on the tension between FDA career scientists (June 29-30 briefing documents concluding all seven peptides have insufficient evidence for 503A eligibility) and HHS Secretary RFK Jr.'s public push to expand peptide compounding access. Combined with NPR's July 8 nationally syndicated feature ('What's behind the push to make peptide therapies more readily available'), the two consecutive mainstream-outlet beats push the panel-composition and evidence-base story past trade press (Endpoints, STAT, FiercePharma) and into general-audience awareness heading into the July 23-24 vote at White Oak.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
The Alabama Board of Medical Examiners and Medical Licensure Commission issued a formal notice on May 26, 2026 prohibiting physicians, physician assistants, certified registered nurse practitioners, and certified nurse midwives from prescribing, administering, dispensing, recommending, or supplying any non-FDA-approved research-grade peptide to a patient. The notice explicitly declares patient consent forms acknowledging research-grade status ineffective and unable to mitigate professional or legal liability. Chairman Rogers cited the lack of FDA review as the basis: substances that have not gone through FDA review cannot be reliably verified for identity, manufacturing process, or risk profile. The state-level prohibition arrived alongside the FDA's April 23 removal of 12 peptides from Category 2 ahead of the July 23-24 PCAC meeting, illustrating that state-board enforcement is now layering on top of federal regulatory action.
The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list enters its final two weeks of public comment on June 15. The 60-day comment window closes June 29, after which the agency will weigh comments and issue final rulemaking. Once finalized, the rule will prohibit 503B outsourcing facilities from bulk-compounding these GLP-1 molecules under any circumstance, including future shortage designation. The 503A pathway through licensed pharmacies remains intact ahead of the July 23-24 PCAC peptide-compounding advisory meeting, but the trajectory for large-scale GLP-1 compounding is fixed. Telehealth platforms (Hims & Hers, LifeMD, others) had already migrated to branded supply via Novo and Lilly partnerships since Q1 2026.
The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.
A June 9 Pharmacy Times analysis broke down what HHS Secretary Robert F. Kennedy Jr.'s February 27 announcement of Category 2 to Category 1 reclassification actually means for licensed compounding pharmacies. The piece emphasized that reclassification does not mean FDA approval and that BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C still need PCAC review on July 23-24 before formal addition to the 503A bulks list. Google search volume for 'peptides' rose from 1.3 million per month in 2024 to roughly 8 million per month in 2026.
A STAT and Undark investigation, supported by the Pulitzer Center and widely republished around June 1-2, examined the thin evidence behind BPC-157, the wound-healing peptide on the FDA's July 23-24 PCAC docket. Nearly all of the roughly 200 BPC-157 studies indexed on PubMed list Croatian researcher Predrag Sikiric or colleague Sven Seiwerth as an author, a concentration a Polish review team flagged as a confirmation-bias risk, and Sikiric's undisclosed conflicts include patents dating to 1989 and a CEO role at Diagen, which sells a patented version. Only three human studies have been published; STAT ran a June 1 follow-up carrying Sikiric's response to skeptics.
Umbrella Labs announced Tuesday May 19 a documentation and traceability update for its dihexa peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's ongoing standardization initiative focused on identity-field consistency, record continuity, and reproducibility support for research laboratories. The timing aligns with the FDA-confirmed February 2027 PCAC meeting that will review dihexa acetate for potential 503A bulks-list inclusion alongside GHK-Cu, Melanotan II, LL-37, and PEG-MGF. Dihexa is a small angiotensin IV-derived peptide originally studied at Washington State University for hepatocyte growth factor activation and neuroprotection. Reference-material traceability standards are a soft signal of the regulatory cycle compounding pharmacies and supply chains are preparing for ahead of the PCAC review.
The FDA announced an AI-Informed Inspection Pilot on May 15, 2026, applying machine-learning analysis to facility inspection prioritization and execution. The program is part of the FDA's Pharmaceutical Quality/Manufacturing Standards initiative and will affect peptide-manufacturing sites including 503A compounding pharmacies, 503B outsourcing facilities, and full-scale peptide CDMOs. AI inputs include historical inspection findings, FAERS adverse-event signals, supply-chain risk indicators, and recall history. The pilot lands during a sensitive compounding-pharmacy regulatory cycle ahead of the July 23-24 PCAC meeting on seven peptides for 503A bulks-list inclusion (BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon) and against the April 30 503B bulks-list proposal closing comments June 29. Industry response is mixed: faster inspection cycles could ease compliance burden for well-run facilities but may concentrate enforcement on the gray-market segment.
Wall Street's read of Hims & Hers' Q1 print delivered May 11 split between two camps. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed) on what analysts called a 'mixed' quarter, citing gross margin compression from 73% to 65% on the wind-down of compounded semaglutide. Canaccord raised its target to $32 from $30 (Buy) framing the quarter as a transition speed bump rather than a thesis break. The central question both calls land on: whether branded Novo Nordisk Wegovy/Ozempic distribution (live since March 26) can offset margin loss from the compounded business. Q1 books closed March 31, so meaningful Wegovy revenue contribution comes in Q2; subscriber count held at 2.6M (+9% YoY).
The FDA updated its Section 503A bulks drug substances list on May 14, 2026, continuing the rolling-status changes leading into the July 23-24 PCAC meeting that will evaluate seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) for potential 503A-bulks-list inclusion. The April 30 503B bulks-list proposal (closing June 29) is moving in parallel toward effectively ending large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. The combined regulatory cycle through July 24 will reshape the compounding-pharmacy economy for the next 2-3 years and determine which research peptides remain accessible through licensed channels.
Hims & Hers reported Q1 2026 after market close May 11: revenue $608.1M (+4% YoY vs $586M prior year), missing the $616.9M consensus; subscribers up 9% to 2.6M; net loss of $92.1M ($0.41/share) vs $49.5M net income in Q1 2025. Gross margin compressed from 73% to 65% on the strategic pivot away from compounded semaglutide toward branded Novo Nordisk Wegovy/Ozempic supply (live since March 26). Q1 closed March 31 — meaningful Wegovy revenue contribution lands in Q2. Full-year 2026 guidance was raised: revenue to $2.8-3.0B and Adjusted EBITDA to $275-350M. The company is keeping limited compounded GLP-1 access alive alongside branded supply, threading the FDA April 30 503B bulks-list proposal.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
Foley & Lardner published a May 2026 client memo translating the FDA's April 22 Category 2 removal of 12 peptides for the compounding-pharmacy audience. Key framing: the removal does not, by itself, place these substances on the 503A bulks list, and the peptides will exist in a regulatory gray zone until the PCAC meets July 23–24 to consider seven of them (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) and the FDA takes final action — which under standard rulemaking timelines could run more than a year past the meeting. The piece joins the Orrick May 2026 503B GLP-1 memo, the FDA Law Blog Pep(tide) Rally analysis (April 23), Holt Law's California Sherman-Law alert, and the Frier Levitt April peptide update as the legal cluster compounders are reading ahead of the meeting.
Drexel University's news desk ran a May 5 Q&A on peptide popularity and safety, framed by the FDA's April Category 2 removals and the upcoming July 23–24 PCAC meeting on seven peptides for the 503A bulks list. The piece covers why peptides are surging — easier and cheaper synthesis since the 1980s genetic-engineering era, plus newer molecules like GLP-1 with broad therapeutic effects — and the safety gaps: pharmacy-to-pharmacy compounding variability, supply not keeping up with demand, and a gray-market problem that pushes patients to unverified online sources. The Q&A joins the AMA, AJMC, Pharmacy Times, MIT Technology Review, and the American Council on Science and Health pieces in the post-Category-2 consumer-education ecosystem.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.